Blood-Brain Barrier CML Chronic Myeloid Leukemia
''The blood–brain barrier (BBB) is a separation of circulating blood from the brain extracellular fluid (BECF) in the central nervous system (CNS). It occurs along all capillaries and consists of tight junctions around the capillaries that do not exist in normal circulation. Endothelial cells restrict the diffusion of microscopic objects (e.g. bacteria) and large or hydrophilic molecules into the cerebrospinal fluid (CSF), while allowing the diffusion of small hydrophobic molecules (O2, CO2, hormones). Cells of the barrier actively transport metabolic products such as glucose across the barrier with specific proteins. This barrier also includes a thick basement membrane and astrocytic endfeet.''
Extract from Blood-Brain Barrier (in Wikipedia)
Understanding of the blood–brain barrier (BBB) is important to understand later how it can be affected by TKIs. For instance, it's important to know that Imatinib reduces the blood-brain barrier permeability and Dasatinib crosses the blood-brain barrier.
VIDEOS
The Blood Brain Barrier
October 3, 2015, Anatomy and Physiology by M. Roehrs
The Blood-Brain Barrier
September 14, 2010, TheMizzouTube
The Blood Brain Barrier
October 3, 2015, Anatomy and Physiology by M. Roehrs
The Blood-Brain Barrier
September 14, 2010, TheMizzouTube
ARTICLES
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report
February 3, 2015, Oncology Letter
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
August 7, 2012, BMC Hematology
Scientists Say Anticancer Drug Imatinib Can Stop Morphine Tolerance
Feb 20, 2012, Gen NewsHighlights
Olfactory Targeting Through Intranasal Delivery of Biopharmaceutical Drugs to the Brain -- Current Development
June 13, 2011, Discovery Medecine
Pericytes regulate the blood-brain barrier.
November 25, 2010, PubLMed
Guards of the Blood-Brain Barrier Identified
October 15, 2010, US News Science
Key to blood-brain barrier opens way for treating Alzheimer's and stroke
October 14, 2010, EurekAlert
Three Paths to Better Tyrosine Kinase Inhibition Behind the Blood-Brain Barrier in treating CML and Glioblastoma with Imatinib
February 2010, Translational Oncology
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
April 2009, Clinical cancer Research
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
August 15, 2008, Journal Blood
Imatinib (Gleevec) May Widen Window for tPA in Stroke
June 23, 2008, MedPage Today
Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier
December 2006, Drug metabolism & disposition
The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
April 1, 2005, Cancer Research
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report
February 3, 2015, Oncology Letter
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
August 7, 2012, BMC Hematology
Scientists Say Anticancer Drug Imatinib Can Stop Morphine Tolerance
Feb 20, 2012, Gen NewsHighlights
Olfactory Targeting Through Intranasal Delivery of Biopharmaceutical Drugs to the Brain -- Current Development
June 13, 2011, Discovery Medecine
Pericytes regulate the blood-brain barrier.
November 25, 2010, PubLMed
Guards of the Blood-Brain Barrier Identified
October 15, 2010, US News Science
Key to blood-brain barrier opens way for treating Alzheimer's and stroke
October 14, 2010, EurekAlert
Three Paths to Better Tyrosine Kinase Inhibition Behind the Blood-Brain Barrier in treating CML and Glioblastoma with Imatinib
February 2010, Translational Oncology
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
April 2009, Clinical cancer Research
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
August 15, 2008, Journal Blood
Imatinib (Gleevec) May Widen Window for tPA in Stroke
June 23, 2008, MedPage Today
Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier
December 2006, Drug metabolism & disposition
The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
April 1, 2005, Cancer Research
|
|